🔍Quick Answer
What is PGT-A testing in Dubai?
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is a genetic screening test performed on embryos during an IVF cycle to check for chromosomal abnormalities before transfer. PGT-A testing in Dubai is recommended for women over 35, couples with recurrent miscarriage, and those with repeated IVF failure — helping select only chromosomally normal (euploid) embryos to improve implantation rates and reduce pregnancy loss.
Why Chromosomal Screening Before Transfer Matters
Every IVF cycle begins with a shared goal: a healthy pregnancy and a healthy baby. Yet one of the most persistent causes of IVF failure and early pregnancy loss is not the clinical process itself — it is chromosomal abnormality within the embryo. An embryo can appear morphologically perfect under a microscope and still carry an incorrect number of chromosomes, making implantation unlikely or miscarriage almost inevitable.
PGT-A testing in Dubai addresses this directly. By screening embryos for aneuploidy — the presence of too many or too few chromosomes — before the embryo is transferred to the uterus, PGT-A gives clinicians and patients a critical additional layer of information. It does not replace careful embryo culture or expert clinical judgement, but it significantly sharpens the selection process in ways that visual assessment alone cannot.
At Best Life Fertility Center, PGT-A testing in Dubai is offered as a targeted, evidence-informed tool — not a mandatory checkbox, but a clinically meaningful addition for the right patients at the right stage of their IVF journey. This guide explains exactly what the process involves, what the evidence says, who it helps most, and what to expect at every step.
What Is PGT-A? The Science Explained Simply
Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a laboratory procedure performed during an IVF cycle to analyse the chromosomal makeup of embryos before they are transferred to the uterus.
Human cells normally contain 46 chromosomes — 23 from the egg and 23 from the sperm. When an embryo has the correct number (46), it is described as euploid. When it has too many or too few chromosomes, it is described as aneuploid.
📌Key Fact
Aneuploidy is one of the leading causes of IVF implantation failure, early pregnancy loss, and chromosomal conditions such as Down syndrome (trisomy 21), Turner syndrome (monosomy X), and others. The risk increases significantly with maternal age.
PGT-A does not test for specific inherited single-gene disorders (that is the role of PGT-M), nor does it assess structural chromosomal rearrangements (PGT-SR). Its specific function is counting chromosomes — confirming whether each embryo has the correct total of 46.
How PGT-A Fits Into the IVF Process: Step by Step
PGT-A does not run in isolation — it is integrated into the standard IVF cycle, with one additional laboratory stage:
Stage | What Happens |
Ovarian stimulation | Hormones stimulate the ovaries to produce multiple eggs in one cycle |
Egg retrieval | Mature eggs are collected under sedation via ultrasound-guided aspiration |
Fertilisation (IVF/ICSI) | Eggs are fertilised with sperm in the embryology laboratory |
Embryo culture | Embryos develop to blastocyst stage — typically day 5 or 6 |
Embryo biopsy | A few cells (4–8) are removed from the trophectoderm — the outer layer that forms the placenta, not the embryo itself |
PGT-A analysis | Biopsied cells are sent to a genetics laboratory for chromosomal analysis (results typically take 3–5 days) |
Embryo vitrification | Embryos are frozen while awaiting results |
Euploid embryo transfer | A chromosomally normal embryo is selected and transferred in a subsequent frozen embryo transfer (FET) cycle |
Pregnancy test | Blood test 10–14 days after transfer confirms implantation |
💡 Important Note
The biopsy removes cells from the outer layer (trophectoderm) — the cells that will eventually form the placenta. The inner cell mass, which develops into the baby, is left entirely undisturbed. Published evidence confirms that trophectoderm biopsy does not impair embryo development or reduce implantation potential when performed by an experienced embryologist.
Who Benefits Most from PGT-A Testing in Dubai?
PGT-A is not recommended as a routine screening tool for every IVF patient. Current evidence supports its use in specific clinical scenarios where the probability of aneuploidy is meaningfully elevated — making the additional information it provides most clinically relevant.
✅ PGT-A Is Particularly Recommended For:
Patient Profile | Why PGT-A Helps |
Women aged 35 and over | Chromosomal abnormality rates in eggs rise sharply with maternal age — PGT-A filters out aneuploid embryos that would otherwise be transferred |
Couples with recurrent miscarriage (2+ losses) | Many unexplained miscarriages are chromosomally driven; PGT-A identifies transferable euploid embryos to reduce repeat loss |
Patients with repeated IVF implantation failure | Where morphologically good embryos have consistently failed to implant, PGT-A may identify a chromosomal factor previously undetected |
Known chromosomal rearrangements (translocations/inversions) | Structural chromosomal abnormalities in a parent significantly increase the proportion of aneuploid embryos produced |
Couples opting for single embryo transfer | PGT-A helps confidently select which single embryo to transfer, supporting safe SET without reducing success rates |
Women with diminished ovarian reserve | When only a small number of embryos are produced, selecting the most viable one for transfer is especially important |
⚠ Where PGT-A May Not Be Necessary:
- Women under 35 with good ovarian reserve and multiple high-quality blastocysts, where cumulative live birth rates with conventional IVF can be comparable
- Cycles producing very few embryos, where biopsy and testing risk reduce the already limited embryo pool
- Where biopsy results are inconclusive (mosaic), embryos would significantly reduce transferable options
Your specialist at Best Life Fertility Center will discuss whether PGT-A is appropriate for your specific clinical picture — not as a default add-on, but as a targeted decision.
What the Evidence Says: PGT-A and IVF Outcomes
The clinical evidence around PGT-A is more nuanced than a simple “it always works” or “it doesn’t work” narrative — and understanding this nuance is part of receiving genuinely expert guidance.
A 2023 systematic review and meta-analysis published in the Journal of Assisted Reproduction and Genetics (PMC), evaluating 16 studies including 6 randomised controlled trials, found a statistically significant benefit from PGT-A on the composite outcome of live birth rate and ongoing pregnancy per embryo transfer, with the benefit being more pronounced in women aged 35 and over and in cohort studies with higher baseline aneuploidy rates.
However, it is important to note what the ASRM’s 2024 Committee Opinion makes clear: the value of PGT-A as a routine screening test for all IVF patients has not been definitively demonstrated in large multicenter randomised trials. The evidence is strongest for specific subgroups — particularly older women and those with recurrent pregnancy loss — which is precisely why targeted, individualised use of PGT-A produces the best patient outcomes.
📊PGT-A at a Glance: What the Evidence Supports
✅ Improves implantation rates per transfer in selected patients
✅ Reduces miscarriage rates by avoiding aneuploid embryo transfers
✅ Particularly beneficial for women 35+ and recurrent pregnancy loss
✅ Enables safe, confident single embryo transfer
⚠️ Does not benefit all patients equally — younger women with good prognosis may not see cumulative live birth benefit
⚠️ Mosaic embryo results require careful specialist interpretation
Understanding Mosaic Embryo Results
One aspect of PGT-A that deserves specific attention is the mosaic result — a finding that many patients are not prepared for and can cause significant anxiety.
A mosaic embryo is one in which some cells carry the correct number of chromosomes (euploid) and others do not (aneuploid). Mosaicism occurs naturally during embryo development and does not automatically mean the embryo cannot result in a healthy pregnancy.
Current guidance from reproductive genetics bodies distinguishes between:
- Low-level mosaicism (<50% abnormal cells): May be suitable for transfer, with careful counselling
- High-level mosaicism (>50% abnormal cells): Generally advised against transfer, though outcomes vary by chromosome involved
If a mosaic result is received, your specialist and a genetic counsellor will review the specific finding in context — the chromosome involved, the level of mosaicism, and how many other euploid embryos are available — before recommending next steps.
PGT-A vs. Standard Morphological Assessment: A Comparison
Standard IVF (Morphology Only) | IVF with PGT-A | |
Embryo selection basis | Visual appearance (shape, cell number, fragmentation) | Chromosomal analysis + appearance |
Can detect aneuploidy? | No | Yes |
Transfer of aneuploid embryos | Possible | Significantly reduced |
Miscarriage risk | Higher (especially in older women) | Reduced |
Number of transfers to achieve pregnancy | May be higher | Often fewer |
Suitable for single embryo transfer? | With caution | With greater confidence |
Additional cost | No | Yes (biopsy + laboratory analysis) |
Requires freeze-all cycle? | Not always | Yes |
What Happens If All Embryos Are Aneuploid?
This is one of the most difficult outcomes of PGT-A, and it happens — particularly in older women or those with very low ovarian reserve. If all embryos from a cycle test aneuploid, there are no euploid embryos to transfer from that cycle.
In this situation, your specialist will discuss:
- Repeating the IVF cycle — to produce additional embryos for testing, ideally accumulating euploid embryos across multiple cycles before transferring
- Adjuvant strategies — such as adjusting stimulation protocols, incorporating diminished ovarian reserve treatment options, or exploring PRP ovarian rejuvenation
- Donor egg IVF — where the cause is age-related egg quality decline, donor eggs from a younger woman significantly reduce aneuploidy rates in the resulting embryos
- Mosaic embryo transfer — where no euploid embryos exist, transfer of a low-level mosaic embryo may be considered with full counselling
No single outcome is the end of the road. At Best Life Fertility Center, our team will always present the full picture of available next steps with honesty and clinical clarity.
PGT-A Testing in Dubai: Why Location Matters
Dubai is recognised as one of the most advanced centres for reproductive medicine in the Middle East and Gulf region. For couples considering PGT-A, the quality of the genetics laboratory partner, the embryology team performing the biopsy, and the regulatory framework governing the procedure all directly affect outcome quality.
Key advantages of undergoing PGT-A testing in Dubai include:
- DHA-licensed fertility centres regulated under Dubai Health Authority standards
- Access to internationally accredited genetics laboratories for chromosomal analysis
- Experienced embryologists trained in trophectoderm biopsy — the technical precision of the biopsy significantly affects result quality
- Integrated genetic counselling before and after testing, ensuring results are interpreted in context
- International patient support — Best Life Fertility Center serves patients from across the UAE, GCC, Europe, Africa, and Asia, with full continuity of care
Conclusion
PGT-A testing in Dubai represents one of the most significant advances in IVF technology — not because it replaces clinical judgement, but because it adds a layer of genetic insight that visual embryo assessment alone cannot provide. For the right patients — women over 35, those with recurrent miscarriage, repeated IVF failure, or known chromosomal risk factors — PGT-A testing in Dubai can meaningfully improve the efficiency of treatment, reduce the emotional and physical burden of failed transfers, and increase the likelihood of a healthy pregnancy in fewer cycles.
At Best Life Fertility Center, our approach to PGT-A is evidence-based and patient-centred: recommended when the clinical picture supports it, explained thoroughly before any decision is made, and interpreted with full genetic counselling when results require careful consideration. If you are planning an IVF cycle and want to understand whether PGT-A is the right choice for your situation, we are here to help you find that answer with clarity and confidence.
Book your IVF and PGT-A consultation at Best Life Fertility Center →
Frequently Asked Questions
Q: Is PGT-A testing in Dubai painful or risky for the embryo?
The embryo biopsy samples outer-layer cells only, leaving the embryo’s inner mass untouched. It is safe and does not impair embryo viability when performed correctly.
Q: How long does it take to get PGT-A results in Dubai?
Results from the genetics laboratory are typically available within three to five days, during which embryos remain safely vitrified (frozen) in the clinic.
Q: Does PGT-A guarantee a successful IVF pregnancy?
No. PGT-A improves the selection process significantly, but implantation success also depends on uterine receptivity, embryo quality, and other individual factors.
Q: Can PGT-A also determine the baby's gender?
Yes. Chromosomal analysis reveals the sex chromosomes (XX or XY). In Dubai, gender selection for family balancing purposes is permitted within UAE regulatory guidelines.
Q: Is PGT-A worth the additional cost for someone under 35?
For younger women with good ovarian reserve and multiple blastocysts, the benefit is less clear. Your specialist will advise based on your individual cycle data and clinical history.
